Viewing Study NCT01710592


Ignite Creation Date: 2025-12-24 @ 3:29 PM
Ignite Modification Date: 2025-12-25 @ 3:02 PM
Study NCT ID: NCT01710592
Status: COMPLETED
Last Update Posted: 2013-01-10
First Post: 2012-10-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
Sponsor: Cancer Trials Ireland
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module